These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 26028493)

  • 1. [Molecular biology of castration-resistant prostate cancer].
    Doucet L; Terrisse S; Gauthier H; Pouessel D; Le Maignan C; Teixeira L; Culine S
    Bull Cancer; 2015 Jun; 102(6):497-500. PubMed ID: 26028493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The concept and mechanisms of castration-resistant prostate cancer].
    Naito S; Shiota M
    Nihon Rinsho; 2014 Dec; 72(12):2090-4. PubMed ID: 25518339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor co-regulatory networks in castration-resistant prostate cancer.
    Sung YY; Cheung E
    Endocr Relat Cancer; 2014 Feb; 21(1):R1-R11. PubMed ID: 24152433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of dihydrotestosterone-inactivation activity promotes prostate cancer castration resistance detectable by functional imaging.
    Zhu Z; Chung YM; Sergeeva O; Kepe V; Berk M; Li J; Ko HK; Li Z; Petro M; DiFilippo FP; Lee Z; Sharifi N
    J Biol Chem; 2018 Nov; 293(46):17829-17837. PubMed ID: 30262668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Qualitative and quantitative hormonal regulation in castration-resistant prostate cancer].
    Murez T; Basset V; Audenet F; Lebret T; Branchereau J
    Prog Urol; 2013 Oct; 23 Suppl 1():S1-8. PubMed ID: 24314734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism.
    Shih JW; Wang LY; Hung CL; Kung HJ; Hsieh CL
    Int J Mol Sci; 2015 Dec; 16(12):28943-78. PubMed ID: 26690121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic targeted approaches on androgen receptors in prostate cancer].
    Ferrand FR; Pavic M
    Rev Med Interne; 2014 Oct; 35(10):670-5. PubMed ID: 24934766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [ASC-J9 for castration-resistant prostate cancer].
    Yamashita S; Arai Y
    Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The transcriptional programme of the androgen receptor (AR) in prostate cancer.
    Lamb AD; Massie CE; Neal DE
    BJU Int; 2014 Mar; 113(3):358-66. PubMed ID: 24053777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptors in early and castration resistant prostate cancer: friend or foe?
    Pelekanou V; Notas G; Stathopoulos EN; Castanas E; Kampa M
    Hormones (Athens); 2013; 12(2):224-35. PubMed ID: 23933691
    [No Abstract]   [Full Text] [Related]  

  • 12. [New generation of androgen receptor antagonist in castration resistant prostate cancer].
    Uemura H
    Nihon Rinsho; 2014 Dec; 72(12):2164-9. PubMed ID: 25518352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current status of castration resistant prostate cancer basic research].
    Sakamoto S; Ichikawa T
    Nihon Rinsho; 2014 Dec; 72(12):2097-102. PubMed ID: 25518340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Androgen receptor variants in prostate cancer].
    Schreyer E; Barthélémy P; Cottard F; Ould Madi-Berthélémy P; Schaff-Wendling F; Kurtz JE; Céraline J
    Med Sci (Paris); 2017; 33(8-9):758-764. PubMed ID: 28945566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanisms of resistance to CYP17A1 inhibitors in castrate resistant prostate cancer].
    Ripert T; Crouzet S; Ploussard G; De La Taille A; Robert G
    Prog Urol; 2013 Oct; 23 Suppl 1():S16-22. PubMed ID: 24314735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissecting the roles of the androgen receptor in prostate cancer from molecular perspectives.
    Hu J; Wang G; Sun T
    Tumour Biol; 2017 May; 39(5):1010428317692259. PubMed ID: 28475016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
    Bastos DA; Dzik C; Rathkopf D; Scher HI
    Oncology (Williston Park); 2014 Aug; 28(8):693-9. PubMed ID: 25140626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC).
    Tsao CK; Galsky MD; Small AC; Yee T; Oh WK
    BJU Int; 2012 Dec; 110(11):1580-8. PubMed ID: 22985411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations.
    Bryce AH; Antonarakis ES
    Int J Urol; 2016 Aug; 23(8):646-53. PubMed ID: 27255944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in the mechanism and drug development of castration-resistant prostate cancer.
    Zuo M; Xu X; Li T; Ge R; Li Z
    Future Med Chem; 2016 May; 8(7):765-88. PubMed ID: 27149562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.